Back to the screen
MLYS
Mineralys Therapeutics, Inc.
Biotechnology · Healthcare · United States
17.00
close · Nov 4, 2026
value
82
cheaper than peers82
quality
26
stronger fundamentals26
ranked against
Biotechnology (pre-revenue)
value · 9 inputs
quality · 3 inputs
110 peerswide variation
Value inputs
| measure | company | vs peers |
|---|---|---|
| earnings yield, 3 years ago | -4.5% | 90 |
| cash flow yield, 3 years ago | -1.9% | 85 |
| earnings yield, 2 years ago | -11.7% | 72 |
| cash flow yield, 2 years ago | -5.4% | 69 |
| cash flow yield, latest year | -9.5% | 67 |
| earnings yield, latest year | -13.5% | 63 |
| cash flow yield, 1 year ago | -11.1% | 59 |
| earnings yield, 1 year ago | -21.5% | 57 |
| price to book | 2.73× | 44 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
|---|---|---|
| operating margin | 0.0% | 50 |
| return on equity | -80.9% | 37 |
| debt to equity | 17.7% | 29 |
3 of 4 measures available
Facts
| market cap | $2B |
|---|---|
| free cash flow | -$203.5M |
| employees | 76 |
| first trade | Feb 10, 2023 |
| next earnings | Nov 4, 2026 |
| fundamentals updated | Nov 4, 2026 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| diluted eps | -2.29 | -3.66 | -1.99 | -0.76 | not reported |
| free cash flow | -$142.4M | -$166.4M | -$81.2M | -$29.2M | not reported |
| net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | not reported | -$657,000 |